---
title: 'Senior Scientist II, Computational Biology at Eikon Therapeutics'
canonical: 'https://feeny.ai/job/senior-scientist-ii-computational-biology-eikon-therapeutics-millbrae-ygmkgzq2eh2x'
type: 'job'
last_seen: '2026-10-25'
---

# Senior Scientist II, Computational Biology at Eikon Therapeutics

- **Company:** Eikon Therapeutics
- **Location:** Millbrae, CA
- **Posted:** 2026-10-23
- **Last confirmed live:** 2026-10-25
- **Apply:** https://job-boards.greenhouse.io/eikontherapeutics/jobs/5274146007

## Job description

Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells, thereby unlocking otherwise intractable classes of proteins as drug targets.

Position

We seek a Senior Scientist in Computational Biology to drive diverse early drug discovery efforts across Eikon’s target portfolio. In this key role, the successful applicant will use their rigorous analytical skills in close collaboration with diverse discovery scientists to conceive and evaluate complex, progress-enabling experiments across our target portfolio. This person will also help shape how Eikon evaluates and adopts novel experimental systems and will partner with colleagues developing quantitative models to ensure that emerging computational methods remain grounded in sound biological reasoning.

## About You

For this role, we are seeking an experienced, rigorous, and results-driven computational scientist with a strong track record driving high impact contributions to advance early research drug discovery programs. You are an enthusiastic and generous collaborator who is skilled in both traditional and emergent drug discovery technologies and is comfortable working in a fast-paced, cross-functional environment uniting diverse disciplines and subject matter experts . This role will require someone who is curious, detail-oriented, and a strategic thinker who can draw on deep technical and biological knowledge to synthesize data from diverse internal and external sources to resolve nuanced scientific questions. You bring both scientific depth and methodological creativity to bear on emerging experimental systems and works closely with quantitative modeling colleagues to ground new computational approaches in strong biological reasoning.

## What You’ll Do

- Drive the development and adoption of novel experimental systems and techniques relevant to Eikon’s target portfolio, collaborating closely with experimental and computational teams across programs.
- Develop and apply analytical approaches, statistical methods, and proof-of-concept tools to support new experimental strategies.
- Analyze multimodal data to evaluate experimental systems, identify enabling insights, and define the limits of interpretation for biological applications.
- Apply statistical, biological, and experimental expertise to evaluate complex experiments. Distill information from diverse sources to reach relevant and testable biological conclusions.

## Qualifications

- Postdoc Fellowship plus 4 years of relevant experience or PhD in bioinformatics, computational biology, or a quantitative field with deep expertise in statistics or method development, plus 7 years of relevant industry experience.
- Hands-on experience developing and applying methods for high-dimensional, multi-modal datasets, including experience designing, evaluating, and integrating high-throughput experiments. Ability to independently define analytical approaches for novel technologies, develop effective solutions, and validate results with minimal oversight.
- Proven experience analyzing complex genomics datasets across one or more technical modalities, such as bulk, single-cell, or spatial transcriptomics, pooled or arrayed CRISPR screens, MAVEs or other multiplexed reporter assays, high content imaging data, Perturb-seq, or other relevant technologies
- Experience working with large consortia and public datasets such as UK Biobank, TCGA, GTEx, ENCODE, gnomAD, and Human Cell Atlas.
- Expertise using one or more high level programming language (e.g., R, Python, or similar) to solve biological problems; well versed in modern coding and computing best practices such as cloud deployment, version control, containerization, etc.
- Demonstrated record of impactful research, evidenced by publications in peer-reviewed journals.
- Excellent interpersonal, written, and verbal communication skills.
- Additional weight will be given to qualified applicants with experience partnering with computational/algorithms teams on statistical or machine learning model development and/or methodological development.

At Eikon, employee compensation also includes bonus and equity compensation, in addition to several generous benefit programs, including:​

- 401k plan with company matching​
- Medical (premiums covered by Eikon at 95%), dental and vision insurance (premiums covered by Eikon at 100%)​
- Mental health and wellness benefits​
- Weeklong summer and winter holiday shutdowns​
- Generous paid time off and holiday policies​
- Life/AD&D Insurance (premiums covered by Eikon at 100%) and optional supplemental employee-paid life/AD&D policies ​
- Enhanced parental leave benefit​
- Daily subsidized lunch program when on-site​

The expected salary range for this role is $191,000 to $231,000 depending on skills, competency, and the market demand for your expertise. Eikon is proud to be an equal opportunity employer and will consider all qualified applicants for employment.

We are currently not accepting any new third-party agencies or firms at this time. Please do not forward unsolicited agency resumes to our website, employees or Human Resources. Eikon Therapeutics will not pay fees to any third-party agency or firm associated with unsolicited resumes.

## About Eikon Therapeutics

## Company Overview
- **One-liner**: Eikon Therapeutics is a late-stage clinical biopharmaceutical company that integrates single-molecule imaging, machine learning, and engineering to discover and develop novel therapies for oncology, immunology, and neuroscience.
- **Entity Type**: Public (NASDAQ: EIKN) – originally privately held, went public via a post-IPO equity round in 2026.
- **Headquarters**: Millbrae, California, United States
- **Founded**: 2019
- **Founders**: Not publicly named in the search results; the company was seeded by The Column Group.

## Core Business
- **Primary industry**: Biotechnology research and drug development (therapeutics)
- **Target customers**: Patients with unmet medical needs; the company partners with clinical research organizations, healthcare providers, and regulators.
- **Mission or purpose statement**: “Better insights will lead to better medicines” – the company aims to introduce new therapies that improve and extend life by deeply understanding human disease biology.

## Products & Services
- **EIK10 (TLR7/8 agonist)**: Phase 2 clinical program for solid tumors, leveraging immune response modulation.
- **VCP inhibitor (undisclosed target)**: Phase 1 program in oncology.
- **AR-v7 degrader**: Preclinical/early clinical program targeting androgen receptor splice variant in cancer.
- **PARP1 inhibitor**: Early-stage oncology program; also a CNS-penetrant PARP1 candidate for neuroscience.
- **AR degrader**: Preclinical androgen receptor degrader.
- **Discovery-stage programs**: Multiple undisclosed targets in oncology, immunology, and neuroscience, supported by the company’s single-molecule imaging platform.

## Market Standing
- **Valuation/Market Cap**: Not disclosed in search results; total funding of ~$1.5B as of mid-2026.
- **Key Metrics**:
  - Annual Revenue: $5.6M (reflective of early-stage, pre-commercial biotech).
  - Total Funding: $1.5B (seed, Series A $148M in 2021, Series B $518M in 2022, Series C $106M in 2023, and post-IPO equity of $381.2M in 2026).
- **Notable Investors/Partners**: The Column Group (lead seed/Series A), 18 investors in Series B, and multiple institutional partners across rounds; board includes industry veterans (e.g., Roger Perlmutter, former Merck CEO).
- **Growth Signals**:
  - Headcount grew ~2.7% YoY to 314 employees (2025–2026).
  - Active job postings increased 270% year-over-year (as of mid-2026).
  - Expanding pipeline into immunology and neuroscience beyond oncology.
  - Recent $351M financing event (reported by multiple outlets) to fund late-stage trials.

## Competitive Advantages
- **Proprietary single-molecule imaging platform** that enables real-time observation of protein dynamics at the single-molecule level, providing insights into disease mechanisms that traditional methods miss.
- **Machine learning integration** to analyze massive imaging datasets, accelerating target identification and drug design.
- **Deep bench of scientific talent**: Executives include Roger Perlmutter (CEO, ex-Merck), Roy Baynes (CMO, ex-Merck), and a team drawing from Genentech, Bristol Myers Squibb, Pfizer, and top academic institutions.
- **Cross-disciplinary approach** merging biology, engineering, and computation under one roof, reducing the “translation gap” between discovery and clinic.

## Strategic Focus
- **Advancing late-stage oncology pipeline**: Lead program (TLR7/8 agonist) in Phase 2, with plans to move into pivotal trials.
- **Expanding into new therapeutic areas**: Significant preclinical investment in immunology and neuroscience, with CNS-penetrant PARP1 and AR programs.
- **Continued platform development**: Scaling imaging and machine learning capabilities to enable faster, more precise drug discovery across multiple indications.
- **Building commercial infrastructure**: Post-IPO financing supports preparation for potential product launches and expanded clinical operations.

## Why Work Here
- **Culture**: Values-driven environment prioritizing execution, collaboration, innovation, transparency, respect, and caring for patients and colleagues.
- **Engineering & science fusion**: Opportunity to work at the intersection of advanced imaging, machine learning, and drug development – unique in biotech.
- **Growth trajectory**: Young company with strong funding, public listing, and rapidly expanding pipeline; employees can have significant impact.
- **Compensation**: Competitive base salaries (e.g., Software Engineer ~$140k, Senior Software Engineer ~$167k) plus equity incentives.
- **Work model**: Likely office-based at the Millbrae HQ or satellite labs in Hayward, CA; clinical roles may require travel; no explicit remote/hybrid policy in search results.
- **Perks**: Not detailed, but typical biotech benefits (health, 401k, PTO) are assumed; the company emphasizes a “transparent and inclusive culture” per its values.
- **Employee sentiment**: Overall rating 3.0/5 on LinkedIn (66 reviews); work-life balance 3.2, compensation 3.4, culture 3.0, career opportunities 2.9 – indicating room for improvement in career development.

## Sources
1. [eikontx.com](https://www.eikontx.com/)
2. [eikontx.com/about-us](https://www.eikontx.com/about-us/)
3. [eikontx.com/join-us](https://www.eikontx.com/join-us/)
4. [eikontx.com/pipeline](https://www.eikontx.com/pipeline/)
5. [linkedin.com/company/eikon-therapeutics-inc](https://www.linkedin.com/company/eikon-therapeutics-inc)

## Other roles at Eikon Therapeutics

- [Director, Optical Engineering](https://feeny.ai/job/director-optical-engineering-eikon-therapeutics-millbrae-zervqzv9zc4h) — Millbrae, CA
- [Executive Director, Automation Operations](https://feeny.ai/job/executive-director-automation-operations-eikon-therapeutics-millbrae-egq04879xm15) — Millbrae, CA
- [Lab Operations Supervisor](https://feeny.ai/job/lab-operations-supervisor-eikon-therapeutics-millbrae-x3vbjdmv2xtb) — Millbrae, CA
- [Senior Scientist I, Cheminformatics](https://feeny.ai/job/senior-scientist-i-cheminformatics-eikon-therapeutics-millbrae-2m0m09mnsw8c) — Millbrae, CA
- [Senior Manager, Pharmacovigilance](https://feeny.ai/job/senior-manager-pharmacovigilance-eikon-therapeutics-jersey-city-85a1kxt3zerr) — Jersey City, NJ
- [Clinical Quality Operations Manager](https://feeny.ai/job/clinical-quality-operations-manager-eikon-therapeutics-millbrae-0mczwgq31knh) — Millbrae, CA / Jersey City, NJ
- [Senior Director, Translational Medicine](https://feeny.ai/job/senior-director-translational-medicine-eikon-therapeutics-jersey-city-1697yzqsxsjb) — Jersey City, NJ / Millbrae, CA
- [Associate Director, Clinical Data Management](https://feeny.ai/job/associate-director-clinical-data-management-eikon-therapeutics-jersey-city-6rkwk4ya8pa0) — Jersey City, NJ / Millbrae, CA
- [Scientist, Computational Biology](https://feeny.ai/job/scientist-computational-biology-eikon-therapeutics-millbrae-feqcsff97ncf) — Millbrae, CA
- [Clinical Trial Associate, APAC](https://feeny.ai/job/clinical-trial-associate-apac-eikon-therapeutics-jersey-city-sx9zkksc0crg) — Jersey City, NJ / Millbrae, CA